Second, our study did not include tumor markers, such as CA19-9 and CEA, and clinical syndromes (e.g., multiple endocrine neoplasia syndromes) or genetic syndromes (e.g., mutations in MEN1, VHL, or other relevant genes). The gene discussed is VHL; the disease is neoplasm.